ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 79 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $62,074 | -27.5% | 63,672 | +17.5% | 0.00% | – |
Q1 2024 | $85,592 | +92.1% | 54,172 | -3.6% | 0.00% | – |
Q4 2023 | $44,549 | +4.3% | 56,177 | +2.6% | 0.00% | – |
Q3 2023 | $42,701 | -23.4% | 54,745 | -9.1% | 0.00% | – |
Q2 2023 | $55,719 | +724.5% | 60,237 | +871.6% | 0.00% | – |
Q1 2023 | $6,758 | -25.3% | 6,200 | 0.0% | 0.00% | – |
Q4 2022 | $9,052 | +50.9% | 6,200 | 0.0% | 0.00% | – |
Q3 2022 | $6,000 | -40.0% | 6,200 | 0.0% | 0.00% | – |
Q2 2022 | $10,000 | -33.3% | 6,200 | -20.5% | 0.00% | – |
Q1 2022 | $15,000 | -25.0% | 7,796 | +45.7% | 0.00% | – |
Q4 2021 | $20,000 | -25.9% | 5,351 | 0.0% | 0.00% | – |
Q3 2021 | $27,000 | -59.7% | 5,351 | -65.9% | 0.00% | – |
Q2 2021 | $67,000 | +9.8% | 15,670 | +34.3% | 0.00% | – |
Q1 2021 | $61,000 | +56.4% | 11,671 | +63.0% | 0.00% | – |
Q4 2020 | $39,000 | +56.0% | 7,161 | +138.6% | 0.00% | – |
Q3 2020 | $25,000 | +25.0% | 3,001 | +54.2% | 0.00% | – |
Q2 2020 | $20,000 | +1900.0% | 1,946 | +678.4% | 0.00% | – |
Q1 2020 | $1,000 | – | 250 | 0.0% | 0.00% | – |
Q4 2019 | $0 | -100.0% | 250 | -68.8% | 0.00% | – |
Q3 2019 | $1,000 | -66.7% | 800 | 0.0% | 0.00% | – |
Q2 2019 | $3,000 | -25.0% | 800 | 0.0% | 0.00% | – |
Q1 2019 | $4,000 | -63.6% | 800 | -60.0% | 0.00% | – |
Q4 2018 | $11,000 | -71.1% | 2,000 | -28.6% | 0.00% | – |
Q3 2018 | $38,000 | -22.4% | 2,800 | -33.3% | 0.00% | – |
Q2 2018 | $49,000 | +28.9% | 4,200 | +23.5% | 0.00% | – |
Q1 2018 | $38,000 | +216.7% | 3,400 | +78.9% | 0.00% | – |
Q4 2017 | $12,000 | -25.0% | 1,900 | 0.0% | 0.00% | – |
Q3 2017 | $16,000 | -50.0% | 1,900 | -73.2% | 0.00% | – |
Q2 2017 | $32,000 | -23.8% | 7,100 | -6.6% | 0.00% | – |
Q1 2017 | $42,000 | +600.0% | 7,600 | +442.9% | 0.00% | – |
Q4 2016 | $6,000 | -33.3% | 1,400 | 0.0% | 0.00% | – |
Q3 2016 | $9,000 | -25.0% | 1,400 | 0.0% | 0.00% | – |
Q2 2016 | $12,000 | +71.4% | 1,400 | +75.0% | 0.00% | – |
Q1 2016 | $7,000 | 0.0% | 800 | +33.3% | 0.00% | – |
Q4 2015 | $7,000 | 0.0% | 600 | 0.0% | 0.00% | – |
Q3 2015 | $7,000 | – | 600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM ASSET MANAGEMENT LLC | 5,555,461 | $5,416,574 | 2.98% |
NEA Management Company, LLC | 17,079,778 | $16,651,076 | 1.25% |
EcoR1 Capital, LLC | 27,404,070 | $26,716,228 | 0.82% |
MPM BioImpact LLC | 5,095,912 | $4,968,514 | 0.77% |
PFM Health Sciences, LP | 10,520,231 | $10,256,173 | 0.51% |
Long Focus Capital Management, LLC | 12,346,417 | $12,036,522 | 0.46% |
Matrix Capital Management Company, LP | 38,974,185 | $37,995,933 | 0.29% |
Acuitas Investments, LLC | 541,201 | $527,617 | 0.28% |
TANG CAPITAL MANAGEMENT LLC | 1,743,619 | $1,699,854 | 0.17% |
Key Client Fiduciary Advisors, LLC | 263,989 | $257,363 | 0.13% |